Latest Breaking News On - John barrassor wyoming - Page 3 : vimarsana.com

Murkowski defends funding for school archery and hunter safety education

Washington, D.C. (KINY) - Senator Lisa Murkowski (R-Alaska) this week cosponsored two measures that support students and schools with archery and hunter safety education.

Wyoming could gain the most from federal climate funding, but obstacles remain

Ambitious climate action could reap rewards for the No. 1 coal state, one study concludes. But the state economy remains tied to fossil fuels.

How is Wyoming fairing one-year into the 'most significant' climate policy in U.S. history?

Crapo, Bennet, Buck, Neguse Introduce Bipartisan Water and Agriculture Tax Reform Act

U.S. Senators Mike Crapo (R-Idaho) and Michael Bennet (D-Colorado) have introduced the Water and Agriculture Tax Reform (WATER) Act. The bipartisan legislation reforms outdated tax provisions hindering investment in important

Hageman, Barrasso, Lummis demand cuts ahead of debt ceiling deadline

Hageman, Barrasso, Lummis demand cuts ahead of debt ceiling deadline

Wyoming’s lone U.S. representative and both senators are among congressional Republicans who say they’ll only support a bill to pay the country’s debts if it’s tied to future spending cuts.

Senator Cotton calling for Immediate US withdrawal from New Start Arms Control Treaty

On May 18th, Senator Tom Cotton (R-Arkansas) announced the introduction of the No START Treaty Act, legislation that accuses Russia of

President Biden Wants to Ban Cars, Here are 23 Stocks to Buy

The proliferation of electric vehicles is all but inevitable at this point. These are the stocks to buy for investors who want to profit.

Resolution proposes to redefine 'habitat'

Wyoming Sen. Cynthia Lummis has proposed to set aside a Biden administration revision of a Trump-era definition of “habitat” as defined under the Endangered Species Act, one of several …

Cornyn Blasts Biden Admin's Innovation-Killing Drug Pricing Model

If proposed and finalized as described, this profound policy shift would inevitably chill incentives for leveraging the FDA’s game-changing expedited regulatory avenue, which has served patients with life-threatening diseases for decades. Later approvals and access delays would follow.